PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986

This medicine is to be supplied upon a physician's prescription only

OCALIVA® 5 MG
Film-coated tablets

Composition:
The active ingredient and its quantity:
Each film-coated tablet contains:
obeticholic acid 5 mg

OCALIVA® 10 MG
Film-coated tablets

Composition:
The active ingredient and its quantity:
Each film-coated tablet contains:
obeticholic acid 10 mg

For the list of excipients, please see section 6.

Read this entire leaflet carefully before using this medicine. This leaflet contains concise information about the medicine. If you have any further questions, refer to the physician or pharmacist.
This medicine has been prescribed for the treatment of your illness. Do not pass it on to others. It may harm them, even if you think that their illness is similar to yours.

This medicine is intended for the treatment of adults over the age of 18 years.

1. What is the medicine intended for?

Ocaliva is intended for treatment of adult patients with a type of liver disease known as primary biliary cholangitis (also known as primary biliary cirrhosis), either by itself or together with another medicine, ursodeoxycholic acid.

Therapeutic group: Bile and liver therapy, bile acids and derivatives

OCALIVA contains the active substance obeticholic acid (farnesoid X-receptor agonist) which helps to improve how your liver works by reducing the production and build up of bile in the liver and also reducing inflammation.

2. Before using the medicine:

Do not use the medicine if:

- You are hypersensitive (allergic) to the active ingredient (obeticholic acid) or to any of the other ingredients of this medicine (*see section 6*).
- You have primary biliary cholangitis with liver cirrhosis with symptoms such as fluid in the belly or confusion (decompensated liver cirrhosis).
- You have a complete blockage of the biliary tract (liver, gallbladder and bile ducts).

Special warnings regarding the use of OCALIVA

- Your doctor may need to interrupt or discontinue OCALIVA if your liver function gets worse. Your doctor will do blood tests to monitor the health of your liver when you start treatment and regularly from there on.
- **Before beginning treatment with OCALIVA tell your physician if You experience itching that is difficult to tolerate**. Itching may occur when taking OCALIVA and may sometimes become severe (intense itching or itching over much of your body). Your doctor may prescribe other medicines for treatment of itching or adjust your dose of OCALIVA. If you experience itching that is difficult to tolerate, talk to your doctor.

Children and adolescents:
OCALIVA is not for use in children or adolescents.

Use of OCALIVA with other drugs:
Tell the physician or pharmacist if you are taking or have recently taken any other medicines, including non-prescription drugs and nutrition supplements.

In particular, tell your physician if you are taking bile acid binding resins (cholestyramine, colestipol, colesevelam) used to lower blood cholesterol levels as they may lessen the effect of OCALIVA. If you take any of these medicines, take OCALIVA at least 4 to 6 hours before or 4 to 6 hours after taking bile acid binding resin, giving as much time as possible.

The blood levels of some medicines such as theophylline (a medicine to help breathing) or tizanidine (a medicine to relieve the stiffness and restriction of muscles) may be increased and need to be monitored by your physician while taking OCALIVA. Your physician may need to monitor how well your blood clots when taking medicines such as warfarin (a medicine to help your blood flow) with OCALIVA.

Use of OCALIVA and food:
You can take OCALIVA with or without food.

Pregnancy and breast-feeding:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your physician or pharmacist for advice before taking this medicine.

There is no experience using Ocaliva in pregnancy. As a precautionary measure, you should not take OCALIVA if you are pregnant.

It is not known if this medicine passes into human milk. Your physician will determine whether you should discontinue breast-feeding or discontinue/abstain from OCALIVA therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for you.

Driving and using machines:
This medicine has no or negligible influence on your ability to drive or use machines.

OCALIVA contains sodium:
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

3. How to use OCALIVA

Always use according to the physician's instructions. Check with the physician or pharmacist if you are not sure.
The dosage and administration will be determined by the physician only.

Prior to initiation of treatment with OCALIVA, your hepatic status must be known. If you have primary biliary cholangitis with liver cirrhosis with symptoms such as fluid in the belly or confusion (decompensated liver cirrhosis) or if you have a complete blockage of the biliary tract (liver, gallbladder and bile ducts) this should be determined (see section 2, Special warnings regarding the use of OCALIVA).

The recommended starting dose is one 5 mg film-coated tablet once daily by mouth.
Your doctor may adjust your dose depending on your liver function or if you experience itching that is difficult to tolerate.
Depending on your body's response after 6 months, your physician may increase your dose to 10 mg once daily. Your physician will discuss any change of dose with you.

Do not exceed the recommended dose.

There is no data to support the administration of broken or crushed tablets.

Tests and Follow Up:
Your physician will refer you to perform blood tests to monitor your liver function (see section "Special warnings regarding the use of OCALIVA").

If you have accidentally taken a higher dosage:
If you accidentally take too many tablets, you may experience itching or liver-related side effects such as yellowing of the skin. Contact a physician or go to a hospital for advice immediately.

If you have taken an overdose or if a child has accidentally swallowed the medicine, proceed immediately to a physician or a hospital emergency room and bring the package of the medicine with you.

If you forget to take this medicine:
Skip the missed dose and take your next dose at the regular scheduled time. Do not take a double dose to make up for a forgotten tablet.

If you stop taking this medicine:
Continue with the treatment as recommended by the physician.

Even if there is an improvement in your health condition, do not stop taking this medicine without consulting the physician.

Do not take medicines in the dark! Check the label and the dose <u>each time</u> you take your medicine. Wear glasses if you need them.

If you have any further questions regarding the use of this medicine, consult the physician or pharmacist.

4. <u>Side Effects</u>

Like all medicines, OCALIVA can cause side effects in some users. Do not be alarmed while reading the list of side effects; you may not suffer from any of them.

Tell your physician or pharmacist if you experience itching of the skin (pruritus) or if the itch gets worse while on OCALIVA. In general itching of the skin is a very common side effect that begins within the first month following the start of treatment with OCALIVA and usually becomes less severe over time.

Very common side effects: (affect more than 1 in 10 patients)
- stomach pain
- feeling tired

Common side effects: (affect up to 1 in 10 patients)
- thyroid hormone irregularity
- dizziness
- fast or irregular heart beat (palpitations)
- pain in the mouth and throat
- constipation
- itchy, dry and/or red skin (eczema)
- rash
- pain in your joints
- swelling in the hands and feet
- fever

Side effects with unknown frequency: (frequency cannot be estimated from the available data)
- liver failure
- increase in bilirubin (liver blood test)
- yellowing of the eyes or skin (jaundice)
- scarring of the liver (cirrhosis)

If a side effect appears, if any of the side effects worsen or if you suffer from a side effect not mentioned in this leaflet, consult your physician.

Reporting of side effects
Side effects can be reported to the Ministry of Health by clicking on the link "Report Side Effects of Drug Treatment" that appears on the homepage of the Ministry of Health's website (www.health.gov.il) which links to an online form for reporting side effects, or by the following link: https://sideeffects.health.gov.il
In addition, you can report by emailing the Registration Holder's Patient Safety Unit at: drugsafety@neopharmgroup.com

5. How to store OCALIVA

- Avoid poisoning! This medicine and any other medicine must be stored in a safe place out of the reach and sight of children and/or infants, to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the physician.

- Do not use the medicine after the expiry date (exp. date) stated on the package and bottle. The expiry date refers to the last day of that month.
- Store below 25˚C.
- Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Additional information:

In addition to the active ingredient, OCALIVA also contains:

- Tablet core: Microcrystalline cellulose (E460), sodium starch glycolate (Type A), magnesium stearate.
- Film-coat: Polyvinyl alcohol, part hydrolysed (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), iron oxide yellow (E172).

What OCALIVA looks like and contents of the pack:

- OCALIVA 5 mg is an off-white to yellow, round film-coated tablet with 'INT' on one side and '5' on the other side of the film-coated tablet.
- OCALIVA 10 mg is an off-white to yellow, triangular film-coated tablet with 'INT' on one side and '10' on the other side of the film-coated tablet.

Pack sizes
1 bottle with 30 film-coated tablets.

Registration holder's name and address:
Neopharm Ltd., 6 Hashiloach St. P.O.B 7063, Petach-Tikva 4917001.

Manufacturer's name and address:
Advanz Pharma Limited, Dublin 9, Ireland.

Drug registration numbers at the national medicines registry of the Ministry of Health:
OCALIVA 5 mg: 160-32-35217-00
OCALIVA 10 mg: 160-33-35218-00

Revised in March 2023 according to MOH guidelines.

NEOPHARM